Brief: Hoth Therapeutics Signs VA Research Deal To Advance GDNF As Breakthrough Therapy For Obesity And Fatty Liver
22/07/2025 14:17
July 22 (Reuters) - Hoth Therapeutics Inc HOTH.O: HOTH THERAPEUTICS SIGNS VA RESEARCH DEAL TO ADVANCE GDNF AS BREAKTHROUGH THERAPY FOR OBESITY AND FATTY LIVER - SIDE-BY-SIDE STUDY VERSUS. SEMAGLUTIDE BEGINS HOTH THERAPEUTICS- UNDER DEAL, CO TO SUPPLY GDNF WHILE VA RETAINS DATA RIGHTS AND SHARES DE-IDENTIFIED RESULTS PER HIPAA-COMPLIANT CRADA TERMS Source text: ID:nPn61pGKQa Further company coverage: HOTH.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Rocket One
See all newsBrief: Rocket One Signs AI Chip Development Agreement Targeting Ultra-Low-Power Magnetic Computing
Brief: Rocket One Signs Agreement To Advance Nanomagnetic Ai Chip Technology And Device Prototyping
Brief: Rocket One Signs Patent License Agreement With U.S. Air Force For Technology Designed To Capture And Neutralize Hostile Drones
Brief: Rocket One To Buy 100% Ownership Of Tracer Drone Technologies
Brief: Rocket One And Nasa Reach Agreement To Advance Space Ai Technology